Shire bags paediatric label expansion for Cinryze in the US
US regulators have approved a label expansion for Shire’s Cinryze, allowing its use in children aged six and above with hereditary angioedema.
HEA is a rare, debilitating and potentially life-threatening rare genetic disease that causes swelling in the face, extremities and GI tract, thought to affect around
Cinryze (C1 inhibitor [human]), acquired by Shire through its purchase of ViroPharma in 2014, works by raising plasma levels of C1-INH in patients with the condition, who are prone to swelling due to an underlying deficiency of this protein.
Read more: http://www.pharmatimes.com/news/shire_bags_paediatric_label_expansion_for_cinryze_in_the_us_1241152
HEA is a rare, debilitating and potentially life-threatening rare genetic disease that causes swelling in the face, extremities and GI tract, thought to affect around
Cinryze (C1 inhibitor [human]), acquired by Shire through its purchase of ViroPharma in 2014, works by raising plasma levels of C1-INH in patients with the condition, who are prone to swelling due to an underlying deficiency of this protein.
Read more: http://www.pharmatimes.com/news/shire_bags_paediatric_label_expansion_for_cinryze_in_the_us_1241152